Etop Ibcsg Partners Foundation
Clinical trials sponsored by Etop Ibcsg Partners Foundation, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Brain radiation boost may extend cancer control in lung and melanoma patients Results expected Sep 2026 (estimated)
- New combo therapy aims to extend remission in aggressive lung cancer Results expected Dec 2026 (estimated)
- Hope for breast cancer patients: new drug combo may delay recurrence Results expected Dec 2026 (estimated)
-
Can a bone drug extend life in advanced lung cancer?
Disease control Stopped earlyThis phase III trial tests whether adding denosumab, a drug often used for bone health, to standard chemotherapy helps people with stage IV non-small cell lung cancer live longer. About 595 adults with advanced disease will receive either chemotherapy alone or chemotherapy plus d…
Phase 3 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a lung cancer drug designed for one mutation work for another?
Disease control Stopped earlyThis phase II trial tests whether alectinib, a drug typically used for ALK-positive lung cancer, can shrink tumors or control disease in people with advanced non-small cell lung cancer that has a RET gene rearrangement and has progressed after prior treatment. Participants take a…
Phase 2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Blood protein clues could personalize breast cancer care
Knowledge-focused Stopped earlyThis study investigates whether levels of certain blood proteins—VEGF, soluble HER2, and VCAM-1—change over time in women with hormone-insensitive breast cancer. It compares women who receive maintenance chemotherapy with those who do not, and also looks at whether these protein …
Sponsor: ETOP IBCSG Partners Foundation • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC